ATE169304T1 - Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung - Google Patents

Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung

Info

Publication number: ATE169304T1
Authority: AT; Austria
Prior art keywords: permeability; functional domain; bactericide; biologically active; active peptides
Prior art date: 1993-03-12

Application number

AT94911490T

Other languages

English (en)

Inventor

Roger G Ii Little

Original Assignee

Xoma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-03-12

Filing date

1994-03-11

Publication date

1998-08-15

1993-03-12 Priority claimed from US08/030,644 external-priority patent/US5348942A/en

1994-03-11 Application filed by Xoma Corp filed Critical Xoma Corp

1998-08-15 Application granted granted Critical

1998-08-15 Publication of ATE169304T1 publication Critical patent/ATE169304T1/de

Links

102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
230000000844 anti-bacterial effect Effects 0.000 title abstract 2
239000003899 bactericide agent Substances 0.000 title 1
102000004169 proteins and genes Human genes 0.000 title 1
108090000623 proteins and genes Proteins 0.000 title 1
102100033735 Bactericidal permeability-increasing protein Human genes 0.000 abstract 3
101000871785 Homo sapiens Bactericidal permeability-increasing protein Proteins 0.000 abstract 3
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 2
229960002897 heparin Drugs 0.000 abstract 2
229920000669 heparin Polymers 0.000 abstract 2
238000006386 neutralization reaction Methods 0.000 abstract 2
125000003275 alpha amino acid group Chemical group 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
230000004071 biological effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Ophthalmology & Optometry (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Biochemistry (AREA)
Marine Sciences & Fisheries (AREA)
Pain & Pain Management (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Emergency Medicine (AREA)

AT94911490T 1993-03-12 1994-03-11 Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung ATE169304T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/030,644 US5348942A (en)	1993-03-12	1993-03-12	Therapeutic uses of bactericidal/permeability increasing protein products
US9320293A	1993-07-15	1993-07-15
US18322294A	1994-01-14	1994-01-14

Publications (1)

Publication Number	Publication Date
ATE169304T1 true ATE169304T1 (de)	1998-08-15

Family

ID=27363684

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94911490T ATE169304T1 (de)	1993-03-12	1994-03-11	Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung

Country Status (10)

Country	Link
EP (1)	EP0690872B1 (de)
JP (3)	JP4139863B2 (de)
AT (1)	ATE169304T1 (de)
AU (1)	AU694108B2 (de)
CA (1)	CA2158058C (de)
DE (1)	DE69412243T2 (de)
DK (1)	DK0690872T3 (de)
ES (1)	ES2123134T3 (de)
NZ (1)	NZ263344A (de)
WO (1)	WO1994020532A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5420019A (en)	1993-02-02	1995-05-30	Xoma Corporation	Stable bactericidal/permeability-increasing protein muteins
US5652332A (en) *	1993-03-12	1997-07-29	Xoma	Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5770561A (en) *	1993-07-14	1998-06-23	Xoma Corporation	Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
WO1995002414A1 (en) *	1993-07-14	1995-01-26	Xoma Corporation	Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
WO1995005393A2 (en) *	1993-08-18	1995-02-23	Morphosys Gesellschaft Für Proteinoptimierung Mbh	Lipopolysaccharide-binding and neutralizing peptides
PT759774E (pt) *	1993-09-22	2002-11-29	Xoma Technology Ltd	Metodo para o tratamento de infeccoes bacterianas gram-negativas por administracao de um produto de proteina bactericida indutora da permeabilidade (bip) e de um antibiotico
CA2173611C (en) *	1993-10-05	2005-07-26	Paul A. M. Van Leeuwen	Method of treating depressed reticuloendothelial system function
ATE219684T1 (de) *	1994-01-14	2002-07-15	Xoma Technology Ltd	Anti gram positive bakterielle verfahren und mittel
MX9602570A (es) *	1994-01-14	1997-04-30	Xoma Corp	Metodos y materiales anti-fungosos.
US5447913A (en) *	1994-03-11	1995-09-05	Xoma Corporation	Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5830860A (en) *	1994-03-24	1998-11-03	Regents Of The University Of Minnesota	Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
ATE256147T1 (de) *	1994-09-15	2003-12-15	Xoma Technology Ltd	Peptide gegen pilzen
WO1997004008A1 (en) *	1995-07-20	1997-02-06	Xoma Corporation	Anti-fungal peptides
US5851802A (en) *	1996-03-22	1998-12-22	Xoma Corporation	Methods for recombinant microbial production of fusion proteins and BPI-derived peptides
US5741779A (en) *	1996-05-10	1998-04-21	Xoma Corporation	Antithrombotic materials and methods
DE69703689T2 (de)	1996-05-10	2001-05-10	Xoma Technology Ltd., Berkeley	Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
NZ332954A (en) *	1996-05-23	2000-07-28	Xoma Corp	Use of BPI protein products to treat humans with hemorrhage due to trauma
CA2255865C (en)	1996-05-24	2008-10-14	The Regents Of The University Of Minnesota	Synthesis of soluble beta-sheet forming peptides
US5888973A (en)	1996-08-09	1999-03-30	Xoma Corporation	Anti-chlamydial uses of BPI protein products
US6482796B2 (en)	1996-11-01	2002-11-19	Xoma Corporation	Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6093573A (en) *	1997-06-20	2000-07-25	Xoma	Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
EP0988314B1 (de) *	1997-07-31	2006-07-19	Philip Richard Abraham	Synthetische peptide mit antimikrobiellen und endotoxin-neutralisierenden eigenschaften zur behandlung von sepsis
US6013631A (en) *	1998-06-19	2000-01-11	Xoma Corporation	Bactericidal/permeability-increasing protein (BPI) deletion analogs
US6242219B1 (en)	1999-03-18	2001-06-05	Xoma (Us) Llc	Methods for recombinant peptide production
US6423825B1 (en)	1999-06-25	2002-07-23	Xoma Technology Ltd.	Therapeutic derivative compounds derived from domain II of bactericidal/permeability-increasing protein
DE60008749T2 (de) *	1999-06-25	2005-03-10	Xoma Technology Ltd., Berkeley	Therapeutische peptide aus untersequenzen von bpi
US6515104B1 (en)	1999-06-25	2003-02-04	Xoma Technology Ltd.	Therapeutic peptide-based constructs derived from domain II of bactericidal/permeability-increasing protein
WO2001003724A1 (en) *	1999-07-12	2001-01-18	Xoma Technology Ltd.	Therapeutic uses of bpi protein products for inhibiting h+/k+ atpase activity
AU2003211163A1 (en)	2002-02-20	2003-09-09	Regents Of The University Of Minnesota	Partial peptide mimetics and methods
JP4554370B2 (ja)	2002-03-29	2010-09-29	ゾーマテクノロジーリミテッド	多重遺伝子プラスミドおよび組み換えポリペプチドの発現増加法
SE0301431D0 (sv) *	2003-05-19	2003-05-19	Dermagen	Novel antimicrobial peptides
US7878644B2 (en)	2005-11-16	2011-02-01	Gerber Scientific International, Inc.	Light cure of cationic ink on acidic substrates
GB201319621D0 (en)	2013-11-06	2013-12-18	Norwegian University Of Science And Technology	Antimicrobial agents and their use in therapy
GB201319620D0 (en)	2013-11-06	2013-12-18	Norwegian University Of Science And Technology	Immunosuppressive agents and their use in therapy
GB201507723D0 (en) *	2015-05-06	2015-06-17	Norwegian Univ Sci & Tech Ntnu	Anti-bacterial agents and their use in therapy
GB201507722D0 (en) *	2015-05-06	2015-06-17	Norwegian Univ Sci & Tech Ntnu	Anti-bacterial agents and their use in therapy
CN115894623B (zh) *	2022-12-20	2025-05-13	中国科学院昆明动物研究所	一种具有双重调节dbh和ddc酶活性功能的多肽nr6及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1986006279A1 (en) *	1985-04-30	1986-11-06	Scripps Clinic And Research Foundation	Acute phase protein modulating endotoxic activity of lipopolysaccharides, compositions and methods
EP0563222B1 (de) *	1990-12-03	1998-02-25	New York University	Biologisch aktive bakterizide/permeabilitätserhöhende proteinbruchstücke

1994
- 1994-03-11 ES ES94911490T patent/ES2123134T3/es not_active Expired - Lifetime
- 1994-03-11 DK DK94911490T patent/DK0690872T3/da active
- 1994-03-11 EP EP94911490A patent/EP0690872B1/de not_active Expired - Lifetime
- 1994-03-11 AU AU63988/94A patent/AU694108B2/en not_active Ceased
- 1994-03-11 NZ NZ263344A patent/NZ263344A/xx unknown
- 1994-03-11 WO PCT/US1994/002465 patent/WO1994020532A1/en not_active Ceased
- 1994-03-11 JP JP52025194A patent/JP4139863B2/ja not_active Expired - Fee Related
- 1994-03-11 AT AT94911490T patent/ATE169304T1/de not_active IP Right Cessation
- 1994-03-11 DE DE69412243T patent/DE69412243T2/de not_active Expired - Lifetime
- 1994-03-11 CA CA002158058A patent/CA2158058C/en not_active Expired - Fee Related
2004
- 2004-10-06 JP JP2004294373A patent/JP2005053921A/ja not_active Withdrawn
2007
- 2007-12-27 JP JP2007338237A patent/JP2008101026A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JPH08508248A (ja)	1996-09-03
JP4139863B2 (ja)	2008-08-27
WO1994020532A1 (en)	1994-09-15
DE69412243D1 (de)	1998-09-10
DE69412243T2 (de)	1999-03-25
CA2158058C (en)	2000-08-01
JP2008101026A (ja)	2008-05-01
AU6398894A (en)	1994-09-26
JP2005053921A (ja)	2005-03-03
EP0690872A1 (de)	1996-01-10
HK1014191A1 (en)	1999-09-24
DK0690872T3 (da)	1999-05-10
NZ263344A (en)	1997-08-22
AU694108B2 (en)	1998-07-16
ES2123134T3 (es)	1999-01-01
CA2158058A1 (en)	1994-09-15
EP0690872B1 (de)	1998-08-05

Legal Events

Date	Code	Title	Description
1999-04-15	UEP	Publication of translation of european patent specification
2009-12-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE169304T1 (de)	1998-08-15	Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung
CA2181150A1 (en)	1995-07-20	Biologically Active Peptides from Functional Domains of Bactericidal/Permeability-Increasing Protein and Uses Thereof
BR0007597A (pt)	2001-10-16	Composição hipoalergênica contendo peptìdios tolerogênicos induzindo tolerância oral
DE60323231D1 (de)	2008-10-09	Verkürzte tau proteine
PT749317E (pt)	2002-11-29	Aplicacoes terapeuticas de produtos dimericos de proteinas bactericidas indutoras da permeabilidade
NL300830I1 (nl)	2016-09-28	Protein Q, een recombinant chimeer eiwit, bestaande uit vijf antigenefragmenten van vier verschillende Leishmania infantum (zymodeme Mon-1) eiwitten
DK1025236T3 (da)	2005-10-24	Human checkpoint kinase, HCDS1, præparater og fremgangsmåde
ATE211391T1 (de)	2002-01-15	Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
ATE152353T1 (de)	1997-05-15	Pharmazeutische zubereitungen auf der basis von bakteriozin und deren verwendung zur behandlung gastrointestinaler beschwerden
DE69840024D1 (de)	2008-10-30	Antimikrobielle Peptide, abstammend von Ubiquicidin
DE60138703D1 (de)	2009-06-25	Transportpeptide abgeleitet von erns protein
ATE373091T1 (de)	2007-09-15	Verfahren zur gewinnung und anwendung neuer humaner defensine als biologisch aktive eiweisstoffe zur behandlung von infektionen und anderen erkrankungen
DE69535460D1 (de)	2007-05-24	Pharmazeutische peptide formulierungen zur behandlung von staubmilben allergie
DE60329115D1 (de)	2009-10-15	Tumorantigenprotein und dessen verwendung
DE59410423D1 (de)	2006-01-12	Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
DE69738600D1 (de)	2008-05-08	Neuroaktive peptide
KR100488038B1 (ko)	2005-05-09	기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
ATE346091T1 (de)	2006-12-15	Neues diagnostisches reagens und kit zur erkennung von rickettsiose
BG101846A (bg)	1998-07-31	Варианти на човешка дезоксирибонуклеаза i
DE60234843D1 (de)	2010-02-04	Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten
DE59611330D1 (de)	2006-04-20	Arzneimittel enthaltend wenigstens einen teil des ul84-proteins des cytomegalovirus, verwendung von polypeptiden entsprechend der aminosäuresequenz des ul84-proteins und verfahren zur einführung von ul84 in zielzellen
ATE260934T1 (de)	2004-03-15	Therapeutische peptide aus untersequenzen von bpi
WO1998056810A3 (de)	1999-03-11	Humanes protein lus-i, seine herstellung und verwendung
Critical Care Society of South Africa Working Group	2003	Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated)
BG101847A (bg)	1998-07-31	Варианти на човешка дезоксирибонуклеаза i